Published in Biomed Res Int on May 25, 2014
Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol (2010) 27.58
Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA (2012) 8.94
Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. J Med Chem (2008) 3.09
HIV-1 integrase inhibitor resistance and its clinical implications. J Infect Dis (2011) 1.80
Immaturity of infection control in preterm and term newborns is associated with impaired toll-like receptor signaling. J Infect Dis (2006) 1.66
Declines in low birth weight and preterm birth among infants who were born to HIV-infected women during an era of increased use of maternal antiretroviral drugs: Pediatric Spectrum of HIV Disease, 1989-2004. Pediatrics (2007) 1.64
Howell-Jolly body counting as a measure of splenic function. A reassessment. Clin Lab Haematol (1990) 1.54
Height, weight, and growth in children born to mothers with HIV-1 infection in Europe. Pediatrics (2003) 1.45
Antiretroviral drugs. Curr Opin Pharmacol (2010) 1.42
Impact on weight and height with the use of HAART in HIV-infected children. Pediatr Infect Dis J (2007) 1.30
Expression of the multidrug resistance P-glycoprotein, (ABCB1 glycoprotein) in the human placenta decreases with advancing gestation. Placenta (2005) 1.18
High neonatal concentrations of raltegravir following transplacental transfer in HIV-1 positive pregnant women. AIDS (2010) 1.09
Differential maturation of the innate immune response in human fetuses. Pediatr Res (2004) 1.08
Use of newer antiretroviral agents, darunavir and etravirine with or without raltegravir, in pregnancy: a report of two cases. Antivir Ther (2010) 1.06
Rapid HIV-RNA decline following addition of raltegravir and tenofovir to ongoing highly active antiretroviral therapy in a woman presenting with high-level HIV viraemia at week 38 of pregnancy. J Antimicrob Chemother (2010) 0.99
Safety, tolerability, and efficacy of raltegravir in a diverse cohort of HIV-infected patients: 48-week results from the REALMRK Study. AIDS Res Hum Retroviruses (2013) 0.97
Rapid decline in HIV viral load when introducing raltegravir-containing antiretroviral treatment late in pregnancy. AIDS Patient Care STDS (2012) 0.97
Does exposure to antiretroviral therapy affect growth in the first 18 months of life in uninfected children born to HIV-infected women? J Acquir Immune Defic Syndr (2005) 0.96
Raltegravir in pregnancy: a case series presentation. Int J STD AIDS (2011) 0.95
Pharmacokinetic and safety of raltegravir in pregnancy. Eur J Clin Pharmacol (2012) 0.95
Clinical use of HIV integrase inhibitors: a systematic review and meta-analysis. PLoS One (2013) 0.94
Genetic damage detected in CD-1 mouse pups exposed perinatally to 3'-azido-3'-deoxythymidine and dideoxyinosine via maternal dosing, nursing, and direct gavage. Environ Mol Mutagen (2004) 0.93
Burden of non-AIDS-defining and non-virus-related cancers among HIV-infected patients in the combined antiretroviral therapy era. AIDS Res Hum Retroviruses (2013) 0.91
FDA notifications. FDA approves raltegravir for HIV-1 treatment-naive patients. AIDS Alert (2009) 0.88
Azidothymidine in combination with 5-fluorouracil in human colorectal cell lines: in vitro synergistic cytotoxicity and DNA-induced strand-breaks. Eur J Cancer (1996) 0.87
Pharmacokinetic optimization of antiretroviral therapy in pregnancy. Clin Pharmacokinet (2012) 0.86
Genetic damage detected in CD-1 mouse pups exposed perinatally to 3'-azido-3'-deoxythymidine or dideoxyinosine via maternal dosing, nursing, and direct gavage: II. Effects of the individual agents compared to combination treatment. Environ Mol Mutagen (2004) 0.82
[Pharmacokinetics and interactions of raltegravir]. Enferm Infecc Microbiol Clin (2008) 0.80
Sampling times in micronucleus testing. Mutat Res (1992) 0.79
[Undetectable viral load after the addition of raltegravir in a 36 week pregnant adolescent with high-level HIV viraemia]. An Pediatr (Barc) (2012) 0.79
Folate supplementation of cyclophosphamide-treated mothers diminishes micronucleated erythrocytes in peripheral blood of newborn rats. Environ Mol Mutagen (2004) 0.79
Raltegravir-based HAART regimen in a patient with large B-cell lymphoma. Ann Pharmacother (2009) 0.78
Induction of micronucleated erythrocytes in mouse peripheral blood after cutaneous application of 5-fluorouracil. Arch Med Res (2003) 0.77
Topical pimecrolimus lacks genotoxicity and cytotoxicity by means of micronucleus erythrocyte rodent assay. Drug Chem Toxicol (2011) 0.77
Role of raltegravir in the management of HIV-1 infection. HIV AIDS (Auckl) (2011) 0.77